Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation reports recurring developments across life sciences and diagnostics, including analytical instruments, informatics, service, and high-volume testing workflows. News for WAT commonly covers operating results and guidance, the Analytical Sciences Division, and the Biosciences and Diagnostic Solutions businesses added through the completed BD transaction.
Company updates also include product launches for liquid chromatography, UPLC and UHPLC workflows, MALS detection, rheometry, LC columns, and TA Instruments technologies. Diagnostic news includes FDA-related developments for the Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, along with commercial, conference, and shareholder-related updates.
Waters Corporation (NYSE:WAT) will participate in the Evercore ISI HealthconX Conference on November 29th, 2022. Udit Batra, Ph.D., the President and CEO, will engage in a virtual fireside chat from 1:00-1:45 PM EST. Investors can access the live webcast on the company's investor relations website and a replay will be available for 30 days.
Waters is a global leader in analytical instruments and software, with over 7,800 employees and operations in over 35 countries, specializing in chromatography and mass spectrometry.
Summary not available.
Waters Corporation (NYSE: WAT) reported Q3 2022 sales of $709 million, reflecting a 7% increase as reported and 15% in constant currency. Key highlights include a 21% surge in instrument sales and strong revenue growth across all major geographies, particularly a 23% increase in China. Recurring revenues rose 10% in constant currency. GAAP EPS remained stable at $2.60, while non-GAAP EPS slightly declined to $2.64. Waters raised its full-year 2022 sales growth guidance to 11.5%-12%, despite a 6% unfavorable currency impact. For Q4, it projects sales growth of 6%-8% and non-GAAP EPS of $3.66-$3.76, factoring in currency headwinds.
Waters Corporation has launched the Extraction+ Connected Device, which automates solid phase extraction (SPE) methods, significantly reducing sample preparation time by up to four hours per sample set. This innovation, compatible with the Andrew+ Pipetting Robot and controlled through OneLab Software, minimizes user variability and enhances assay reproducibility. The device is now available globally, marking a step forward in laboratory efficiency for biological, food, forensic, and environmental applications.
Waters Corporation (NYSE:WAT) announced a multi-year investment of up to €6 million, supported by IDA Ireland, to enhance its research and development operations in Wexford, Ireland. This expansion aims to create new scientific jobs and focus on clinical diagnostic solutions. Waters commemorates its 25th anniversary in Ireland, reinforcing its commitment to advancing mass spectrometry technologies for early disease detection. The Wexford facility is vital for manufacturing in-vitro diagnostic systems and aims to improve diagnostic accuracy for various medical conditions.
Waters Corporation (NYSE:WAT) will announce its Q3 2022 financial results in a conference call on November 1, 2022, at 8:00 a.m. ET. The presentation will be accessible through a live webcast on Waters’ investor relations website. A replay option will be available until November 15, 2022, at midnight ET. Waters Corporation has over 60 years of experience in analytical instruments and software, serving various sectors, including life sciences and materials, with a workforce of more than 7,800 employees.
Waters Corporation (NYSE:WAT) has launched advanced powder rheology capabilities for its HR Rheometer, enhancing its versatility in characterizing liquids, solids, and powders. The new SmartSwap™ tooling allows quick transitions between liquid and powder measurements in just 10 seconds, improving sample preparation speed by three times compared to competitors. This innovative technology supports industries like lithium-ion batteries and pharmaceuticals, ensuring accurate data for optimizing materials and processing. The powder rheology accessory is available for existing or new HR Rheometers.
Waters Corporation announced the opening of a new $215M Precision Chemical Manufacturing Facility in location value="LU/us.ma.tauntn"Taunton, Massachusetts, achieving LEED certification from the org value="ACORN:1719435565"U.S. Green Building Council. This facility will enhance production for essential products in the development and testing of vaccines and medicines, creating 25 new jobs and significantly increasing operational efficiency. Waters' facility is the first LEED-certified chemical manufacturing plant in Massachusetts, promoting environmental sustainability in its operations.
Waters Corporation (NYSE:WAT), under CEO Udit Batra, will join the Bank of America 2022 Global Healthcare Conference in London on September 14, 2022, at 9:05 AM BST. Investors can tune into the event via a live webcast on the company’s investor relations website. A recorded replay will be accessible for 30 days post-event. With over 60 years of experience, Waters is a leader in analytical instruments and software, employing 7,800 staff across 35 countries and operating 14 manufacturing facilities.
Waters Corporation (NYSE: WAT) reported second-quarter 2022 sales of $714 million, a 5% increase from the previous year and 10% in constant currency. Instrument sales rose 12% in constant currency, driven by robust performance across product lines. Recurring revenues grew by 8% in constant currency. GAAP EPS was $2.72 and non-GAAP EPS increased 6% to $2.75. For the first half of 2022, sales were $1,405 million, up 9% as reported, with full-year 2022 guidance raised, anticipating 9.5% to 10.5% constant currency sales growth.